Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on: December 21,2023

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on:December 21,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on: December 22,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on:December 22,2023

Research collaboration reveals promising drug candidate for treatment of blood cancers

by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead

Updated on: December 20,2023

Research collaboration reveals promising drug candidate for treatment of blood cancers

by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead

Updated on:December 20,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on: December 20,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on:December 20,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on: December 17,2023

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on:December 17,2023

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on: October 27,2023

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on:October 27,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on: December 22,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on:December 22,2023

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on: December 21,2023

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on:December 21,2023

Study finds association between high insulin dosage and cancer

byOhio UniversityCredit: Unsplash/CC0 Public DomainDr. Yuanjie Mao has led a study published inJAMA Oncologylooking at the correlation between daily insulin dose and cancer incidence

Updated on: December 22,2023

Study finds association between high insulin dosage and cancer

byOhio UniversityCredit: Unsplash/CC0 Public DomainDr. Yuanjie Mao has led a study published inJAMA Oncologylooking at the correlation between daily insulin dose and cancer incidence

Updated on:December 22,2023

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on: December 19,2023

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on:December 19,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023